Search

Art D Sutton

from Severn, MD
Age ~41
Get Report
Also known as:
Art Daniels Sutton, Art Sutton Sutton
Related to:
Jared N Sutton, 50Sonya D Smith, 40Matthew B Messer, 45Amanda Sutton, 45Joann SuttonErick L Smith, 47Melissa L Sutton, 39Fred J Smith, 49Junior Fred SmithJoann Sutton, 68
Connected to:
Abby Sutton, 58Alyssa Sutton, 36Amabra Sutton, 39Amanda K Sutton, 48Anitra Sutton, 45Asim Sutton, 44Audrey A Sutton, 57Banette D Sutton, 45Billy W Sutton, 77Bo D Sutton, 38

Art Sutton Phones & Addresses

  • Severn, MD
  • 702 Applecross Dr, Mebane, NC 27302 (443) 710-1959
  • Mount Pleasant, WI
  • 2360 Ohio Ave, Cincinnati, OH 45219 (513) 684-0349
  • Laurel, MD
  • Baltimore, MD
  • Elyria, OH
  • Brookfield, WI
  • 2360 Ohio Ave, Cincinnati, OH 45219 (513) 602-6876

Work

Position: Food Preparation and Serving Related Occupations

Education

Degree: High school graduate or higher

Emails

a***[email protected]

Resumes

Resumes

Art Sutton Photo 1

Art Sutton

Art Sutton Photo 2

Art Sutton

Location:
United States
Art Sutton Photo 3

Art Sutton

Location:
United States

Publications

Us Patents

N-Acyloxysulfonamide And N-Hydroxy-N-Acylsulfonamide Derivatives

US Patent:
20110144067, Jun 16, 2011
Filed:
Dec 7, 2010
Appl. No.:
12/962572
Inventors:
John P. Toscano - Glen Arm MD, US
Art Sutton - Baltimore MD, US
Vincent J. Kalish - Annapolis MD, US
Frederick Arthur Brookfield - Abingdon, GB
Stephen Martin Courtney - Abingdon, GB
Lisa Marie Frost - Abingdon, GB
International Classification:
A61K 31/635
C07C 303/36
C07D 401/02
C07D 211/00
C07D 265/30
C07D 413/02
A61K 31/63
A61P 9/12
A61P 9/10
US Classification:
514157, 564 42, 544360, 546186, 544106, 544129, 514155, 514156
Abstract:
The invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.

Bis-Acylated Hydroxylamine Derivatives

US Patent:
20110136827, Jun 9, 2011
Filed:
Dec 7, 2010
Appl. No.:
12/962544
Inventors:
John P. Toscano - Glen Arm MD, US
Art Sutton - Baltimore MD, US
Vincent J. Kalish - Annapolis MD, US
Frederick Arthur Brookfield - Abingdon, GB
Stephen Martin Courtney - Abingdon, GB
Lisa Marie Frost - Abingdon, GB
International Classification:
A61K 31/27
C07C 311/51
C07C 311/53
C07D 333/34
C07D 295/185
C07D 307/82
C07C 239/22
C07C 271/08
A61K 31/222
A61K 31/381
A61K 31/495
A61K 31/343
A61K 31/40
A61P 9/00
A61P 9/04
A61P 9/10
A61P 9/12
A61P 35/00
US Classification:
51425501, 560250, 560251, 560 12, 560 13, 549 65, 544390, 549466, 560106, 560 20, 560228, 560227, 560157, 558262, 514507, 514488, 514485, 514445, 514470, 514423
Abstract:
The invention provides certain bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.

Controlled Hno Release Through Intramolecular Cyclization-Elimination

US Patent:
20150291519, Oct 15, 2015
Filed:
Oct 30, 2013
Appl. No.:
14/439800
Inventors:
- Baltimore MD, US
Art D. Sutton - Mount Pleasant WI, US
International Classification:
C07C 311/48
A61K 31/4152
A61K 31/27
A61K 45/06
A61K 31/265
Abstract:
Protected HNO donors designed to undergo non-enzymatic release at neutral pH via an intramolecular cyclization-elimination are disclosed. The rate of cyclization, and therefore HNO release, can be controlled by substituents and chain length. Thus, biologically useful HNO donors having tunable HNO release rates are provided.
Control profile
Art D Sutton from Severn, MD, age ~41 Get Report